Theriva Biologics reports Q1 2026 net loss $2.0M, FDA agrees to Phase 3 design for VCN-01 in PDAC

Theriva Biologics, Inc.

2026-Q1 EPS reported -$0.05 revenue$300,000

Cash and cash equivalents $14.4M as of March 31, 2026; cash runway into Q1 2027.
FDA alignment on Phase 3 trial design for VCN-01 plus gemcitabine/nab-paclitaxel in metastatic PDAC.
New VIRAGE Phase 2b data at AACR 2026 shows improved OS and PFS across subgroups including liver metastases.
Compassionate use of VCN-01 in retinoblastoma started; Phase 2/3 trial expected first patient Dec 2026.
R&D expenses fell 88% to $355K as VIRAGE trial completed; G&A rose 43% to $2.1M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Theriva Biologics, Inc. reported financial results for quarter ended March 31, 2026.

Period: quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 5, 2026, Theriva Biologics, Inc., a Nevada corporation (the “Company”), issued a press release that included financial information for its quarter ended March 31, 2026.

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Theriva Biologics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-055679

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.